Synergistic modulation of cAMP and cGMP rescues hemin-induced plasma membrane fragmentation
Abstract
Hemin, which gets released during erythrocyte lysis, induces concentration-dependent platelet activation, aggregation, and thrombus formation as well as plasma membrane destruction and cytoskeleton reorganization. Classical platelet antagonists do not inhibit the plasma membrane destruction induced by high concentrations of hemin. Both cyclic guanosine monophosphate (cGMP) and adenosine 3':5' -cyclic monophosphate (cAMP) are key endogenous inhibitors of platelet activation. Thus, we investigated whether they inhibit hemin-induced plasma membrane destruction, both individually and in combination. In addition to standard platelet assays, we performed cGMP and cAMP ELISAs, immunoblot analysis of vasodilator-stimulated phosphoprotein (VASP) and immunofluorescence staining. We found that pharmacological modulation of these pathways via NO donors (DEA/NO), soluble guanylyl cyclase (sGC) stimulators (riociguat) or IP receptor agonists (PGE1), and phosphodiesterase (PDE) inhibitors (PDE-5 inhibitor: sildenafil, PDE-3 inhibitor: ibudilast), phosphorylate the downstream vasodilator-stimulated phosphoprotein (VASP) and inhibit hemin-induced platelet activation and degranulation. In particular, synergistically modulation of cGMP and cAMP and the resulted phosphorylation of VASP at Ser239 and Ser157 significantly attenuates platelet aggregation and plasma membrane destruction induced by high concentrations of hemin. Further, the riociguat NO-induced cGMP synthesis was significantly…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.